FEB. 2/2006 9:29AM AVENTIS US PAT DEPT TO: US CENTRALIZED USPTO

RECEIVED CENTRAL FAX CENTER NO. 1588 P.

FEB 0 2 2006

PTO/\$B/21 (09-04) Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ction of information unless it displays a valid OMB control number. <u>Under the Paperwork Reduction Act of 1995, no persons are regulred to respond to </u> Application Number 10/616,945 TRANSMITTAL Filing Date July 11, 2003 First Named Inventor **FORM** Heiner GLOMBIK et al. Art Unit 1623 Examiner Name PESELEV, Elli (to be used for all correspondence after initial filing) Attorney Docket Number DEAV2002/0049 US NP Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC ~ Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affldavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): Request for Refund Express Abandonment Request CD, Number of CD(s) _ Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name AVENTIS PHARMACEUTICALS INC. Signature Printed name Julie Anne Knight Date Rég. No. February 02, 2006 48.867 **CERTIFICATE OF TRANSMISSION/MAILING** I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300 ; Total No. of Pages Transmitted: Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPYO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.41. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPYO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

February 02, 2006

Paul Irvine

Typed or printed name

FEB. 2. 2006 9:30AM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

NO. 1588 P. 2

DEAV2002/0049 US NP

FEB 0 2 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of GLOMBIK, et al.

Examiner:

E. Preselev

__

Art Unit:

1623

Аррисацоп и

Filed:

Title:

Application No.: 10/616,945

July 11, 2003

TELEFAX CERTIFICATE

Novel Thiophene Glycoside Derivatives,

Processes for Their Preparation, Medicaments Comprising These Compounds, and The Use Thereof I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents. Alexandria, VA 22313, on

Pebruary 2, 2006

Sienamre

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

REPLY PURSUANT TO 37 C.F.R. §1.111

Dear Sir:

In response to the Official Action dated November 2, 2005 ("the Action"), reconsideration is respectfully requested in view of the amendments and/or remarks as indicated below:

Amendments to the Claims are reflected in the listing of the claims that begins on page 2 of this paper.

Remarks/Arguments begin on page 17 of this paper.